Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17293434 | 0.89 | KDM4E (0.35) | KDM4EALDH1A1MAPTNPSR1ELANE | |
| SCHEMBL19082745 | 0.87 | KDM4E (0.34) | KDM4EALDH1A1MAPTNPSR1ELANE | |
| SCHEMBL17293486 | 0.84 | CXCR2 (0.38) | KDM4EALDH1A1MAPTNPSR1ELANE | |
| SCHEMBL17293468 | 0.83 | CXCR2 (0.44) | KDM4EALDH1A1MAPTNPSR1 | |
| SCHEMBL17293395 | 0.83 | ELANE (0.35) | ELANE | |
| SCHEMBL17293329 | 0.82 | STS (0.41) | — | |
| SCHEMBL17293274 | 0.82 | ELANE (0.35) | KDM4EALDH1A1MAPTNPSR1ELANE | |
| SCHEMBL19065978 | 0.80 | CXCR2 (0.40) | KDM4EALDH1A1MAPTNPSR1ELANE | |
| SCHEMBL17293299 | 0.80 | CXCR2 (0.40) | KDM4EALDH1A1MAPTNPSR1ELANE | |
| SCHEMBL28391692 | 0.80 | CXCR2 (0.40) | KDM4EALDH1A1MAPTNPSR1ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10336719-B2 | 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-02 | — | — | US | disclosed |
| US-20170190681-A1 | 1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS | Glaxosmithline Intellectual Property Development Limited (GB) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190681-A1 | 1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS | CXCR2, CXCR1, CXCR3 | KDM4E 3420/4885ALDH1A1 1572/4885MAPT 3694/4885 |
| US-10336719-B2 | 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors | CXCR2, CXCR1, CXCR3 | KDM4E 3065/4885ALDH1A1 1449/4885MAPT 3820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.